Juan Du
0000-0003-2538-4007
Changzheng Hospital
12 papers found
Refreshing results…
Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China
Subsequent anti‐myeloma therapy after maturation antigen ( BCMA ) chimeric antigen receptor ( CAR )‐T cell ( HDS269B ) treatment in patients with relapsed/refractory multiple myeloma
CircRNAs: novel therapeutic targets in multiple myeloma
CAR‐T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status
Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
Development and Validation of a Prognostic Implications of Chromosome Abnormalities Algorithm for Newly Diagnosed Multiple Myeloma
Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients
CAG Regimen for Refractory or Relapsed Adult T-Cell Acute Lymphoblastic Leukemia: A Retrospective, Multicenter, Cohort Study
Missing publications? Search for publications with a matching author name.